Tonix Pharmaceuticals plans Phase 2 trial of TNX-102 SL for MDD in 2026, Phase 2/3 of TNX-4800 for Lyme in 2027

Tonix Pharmaceuticals Holding Corp.

Phase 2 trial of TNX-102 SL for major depressive disorder expected to start in 2026.
Phase 2/3 study of TNX-4800 for seasonal Lyme disease prevention expected to start in 2027.
TNX-102 SL is currently FDA-approved for fibromyalgia; this expands its potential indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.